Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-01-07

Clinical Trial Update: Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease [Phase 3]

View source ↗

Summary

Long-term safety and tolerability results from a Phase 3 trial of adalimumab in Crohn's disease are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Humira (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2010-01-07